USA Patent Grants for IMP321 in Cancer
(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwired) -- 02/28/17 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces the granting of patent number 9,579,382 entitled "Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response" by the United States Patent Office.
The method of use claims granted for this patent will provide protection for the treatment of cancer where a plurality of doses of IMP321 is used to generate a monocyte mediated response. Broad claims covering dosage and route of administration have also been granted. As part of the Company's intellectual property strategy, further applications have been filed in the US seeking additional protection for the IMP321 product itself and for use in combination with other reagents. Patent expiry is expected to be 6 July 2029 after a patent term adjustment of 276 days.
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit .
Mr Matthew Beck
The Trout Group LLC
+1 (646) 378-2933
Mr Matthew Gregorowski
Citadel Communications
+61 2 8234 0100
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.03.2017 - 00:30 Uhr
Sprache: Deutsch
News-ID 527195
Anzahl Zeichen: 0
contact information:
Town:
SYDNEY, AUSTRALIA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 201 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"USA Patent Grants for IMP321 in Cancer"
steht unter der journalistisch-redaktionellen Verantwortung von
PRIMA BIOMED LTD (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
